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PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
An antibody against the colony-stimulating factor 1 receptor depletes the resident
subset of monocytes and tissue- and tumor-associated macrophages but does not
inhibit inflammation
*Kelli P. A. MacDonald,1 *James S. Palmer,2 Stephen Cronau,2 Elke Seppanen,2 Stuart Olver,1 Neil C. Raffelt,1
Rachel Kuns,1 Allison R. Pettit,3 Andrew Clouston,4 Brandon Wainwright,2 Dan Branstetter,5 Jeffrey Smith,5
Raymond J. Paxton,5 Douglas Pat Cerretti,5 Lynn Bonham,5 Geoffrey R. Hill,1 and David A. Hume6
1Queensland Institute of Medical Research, Brisbane, Australia; 2Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia; 3Center for
Clinical Research, University of Queensland, Brisbane, Australia; 4Envoi Pathology, Herston, Australia; 5Amgen Inc, Seattle, WA; and 6The Roslin Institute and
Royal (Dick) School of Veterinary Studies, University of Edinburgh, Roslin, United Kingdom
The development of the mononuclear
phagocyte system requires macrophage
colony-stimulating factor (CSF-1) signal-
ing through the CSF-1 receptor (CSF1R,
CD115). We examined the effect of an anti-
body against CSF1R on macrophage ho-
meostasis and function using the MacGreen
transgenic mouse (csf1r-enhanced green
fluorescentprotein)asareporter.Theadmin-
istration of a novel CSF1R blocking anti-
body selectively reduced the CD115Gr-1neg
monocyte precursor of resident tissue
macrophages. CD115Gr-1 inflammatory
monocyteswerecorrespondingly increased,
supporting the view that monocytes are a
developmental series. Within tissue, the an-
tibody almost completely depleted resident
macrophage populations in the peritoneum,
gastrointestinal tract, liver, kidney, and skin,
but not in the lung or female reproductive
organs. CSF1R blockade reduced the num-
bers of tumor-associated macrophages in
syngeneic tumor models, suggesting that
these cells are resident type macrophages.
Conversely, it had no effect on inflammatory
monocyte recruitment in models, including
lipopolysaccharide-induced lung inflamma-
tion, wound healing, peritonitis, and severe
acute graft-versus-host disease. Depletion
of resident tissue macrophages from bone
marrow transplantation recipients actually
resulted in accelerated pathology and exag-
gerated donor T-cell activation. The data
indicate that CSF1R signaling is required
only for the maturation and replacement of
resident-type monocytes and tissue macro-
phages, and is not required for monocyte
production or inflammatory function. (Blood.
2010;116(19):3955-3963)
Introduction
Mononuclear phagocytes may represent 10%-15% of the total cells in
many organs of the body. Their appearance, gene expression profile, and
function are very heterogeneous; the family of cells includes microglia
in the brain, class II major histocompatibility complex (MHC)–
expressing antigen-presenting cells (APCs) associated with most epithe-
lia and mucosal surfaces, and bone-resorbing osteoclasts.1,2 Because of
their extensive functional differences, there are few gene products that
are common to all members of the mononuclear phagocyte system
(MPS).3 In fact, many surface markers, such as the integrins, CD11b and
CD11c, lectin-like molecules, such as sialoadhesin and macrosialin, the
G-protein–coupled receptor, EMR1 (F4/80), and certain chemokine
receptors (eg, CCR1, CCR2, and CX3CR1) are used rather arbitrarily to
divide the MPS into putative functional subsets.3 One molecule that is
expressed on the majority of cells designated as mononuclear phago-
cytes is the receptor for macrophage colony-stimulating factor (CSF-1),
which is a type III integral membrane protein tyrosine kinase encoded
by the c-fms protooncogene (csf1r).4,5 The ligand, CSF-1, controls the
proliferation, differentiation, adaptation, and survival of cells of the
MPS.4,5 In mice, a natural mutation of the csf1 gene, the osteopetrotic
mutation (op/op), or an introduced knock out of the csf1r gene, causes a
very substantial reduction in mononuclear phagocyte numbers in most
tissues of the body. Even though the csf1op/op and csf1r/ mice are
viable, the importance of CSF-1-dependent macrophages in develop-
ment is indicated by a failure to thrive, as well as deficiencies in
development of the central nervous system, pancreas, mammary gland,
and male and female reproductive function.4 The majority of the
phenotypic defects seen in the csf1op/op mice, including reproductive
defects and perturbations in organ development, are even more pen-
etrant in csf1r/ mice.6 Because of the severe pleiotropic effects of
mutation of the csf1 or csf1r genes on normal development, the mutant
animal phenotypes cannot address the physiologic role of CSF-1
receptor (CSF1R) signaling in an adult animal in the steady state. Such
knowledge is clearly important, in light of efforts to produce selective
inhibitors of CSF1R kinase activity.7,8 An alternative approach to using
inhibitors, which have an intrinsic risk of cross-reactivity with related
kinases, is to use antibodies against the ligand or receptor, the latter
being especially relevant with the recent discovery of an alternative
CSF1R ligand, interleukin-34.9
We have previously developed a mouse model in which an
enhanced green fluorescent protein (EGFP) reporter gene is driven
by the csf1r promoter, the MacGreen mouse line.10 In this model,
the reporter gene recapitulated the expression of csf1r mRNA
exclusively in myeloid cells: both mononuclear phagocytes and
neutrophils. In the case of neutrophils, csf1r mRNA is not normally
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translated into protein, although the cells can become CSF-1–
responsive and transdifferentiate into macrophages in response to
CSF-1 after overnight culture.11 The transgenic reporter has been
used in demonstration of CSF-1 dependence/responsiveness of
APCs in lymphoid organs,12 and in direct visualization of macro-
phage roles in tumor progression and metastasis.13 In the current
study, we used these animals as reporters to analyze the actions of a
blocking monoclonal antibody (mAb) against the mouse CSF1R
(CD115) on the MPS at steady state and in models of inflammation
and cancer. The results indicate that the only nonredundant action
of CSF-1 is to promote the maturation of blood monocytes, and
suggest that existing inhibitors of CSF1R may have other activities.
Methods
MacGreen mice10 were backcrossed for 6 generations against a C57BL/6
background and were maintained in a specific pathogen-free facility.
Female C57BL/6 (B6, H-2b) and B6D2F1 (H-2b/d) mice were purchased
from the Animal Resource Center. Unless otherwise indicated, all mice used
were female and aged 6-10 weeks, were housed in sterilized microisolator
cages, and received normal chow and autoclaved water, which was acidified
after transplantation. Approval for all experiments and procedures using
mice was obtained from the Institutional Animal Ethics Committees of The
University of Queensland and The Queensland Institute for Medical
Research. M279 is a rat immunoglobulin G1 (IgG1) mAb that blocks the
ability of CSF-1 to maintain proliferation of a CSF-1–dependent cell line.
The characterization of this reagent and optimization of the treatment
regime is provided in supplemental Methods (available on the Blood Web
site; see the Supplemental Materials link at the top of the online article). The
inflammatory and tumor models used herein, Ab reagents, and staining
protocols, are all standard published methods and are described and
referenced in detail in supplemental Methods and in figure legends.
Results
Anti-CSF1R Ab treatment has little effect on monocytopoeisis
or blood monocyte counts
M279 is a new rat monoclonal IgG1 Ab against mouse CSF1R that,
like the published antibody, AFS98,14 blocks the actions of CSF-1
on a CSF-1–dependent cell line (supplemental Figure 1). In initial
experiments, we examined the effects of anti-CSF1R Ab (M279)
treatment on the cellular composition of lymphoid and peripheral
tissues of MacGreen mice. Utilization of the MacGreen mice
facilitated the monitoring of the depletion of CSF1R cells via
examination of the csf1r-EGFP transgene reporter expression.10,11
Based upon preliminary dose and time-course data (see supplemen-
tal Methods and supplemental Figure 2), we used a prolonged
treatment regime, in which animals were treated 3 weekly for 3
weeks with 400 g of either anti-CSF1R or control rat IgG. After
prolonged Ab treatment, there was a marked decrease in the
absolute number of peritoneal F4/80 macrophages in anti-CSF1R–
treated animals, compared with Ab control-treated animals (Figure
1A). However, there was no significant difference in the cellularity
of bone marrow, blood, or spleen between these groups (Figure
1B). Flow cytometric analysis of EGFP populations including
F4/80 monocytes (not shown), Ly6G granulocytes, CD11b
Figure 1. Effect of anti-CSF1R mAb treatment on myeloid populations within lymphoid tissues. (A) Peritoneal lavage cells from anti-CSF1R and rat IgG-treated mice
stained with phycoerythrin (PE)–conjugated F4/80. Bone marrow, blood, and splenocytes were counted (B) and cell populations enumerated using 3-color flow cytometry (C).
(D) Flow cytometric analysis of EGFP, F4/80, and Gr-1 expression on blood mononuclear cells. In the top panel, the R3 gate contains monocytes that express 3-4-fold higher
F4/80 and csf1r-EGFP, and are completely absent after antibody treatment. In the bottom panel, the R2 gate contains granulocytes, which express both Gr1 and csf1r-EGFP.
These cells can also be seen in the top panel, ungated, expressed csf1r-EGFP, but not F4/80. The R3 gate contains Gr1-positive monocytes, and the R4 gate, Gr1-negative
monocytes. Histograms at right compare the frequency of EGFPF4/80high and EGFPGr-1neg in blood from rat IgG and anti-CSF1R treated MacGreen mice (white and black
bars, respectively). Results shown are from 1 of 2 independent experiments, where n  4-5 animals per group. A value of P  .05 was considered statistically significant (*).
3956 MacDONALD et al BLOOD, 11 NOVEMBER 2010  VOLUME 116, NUMBER 19
 personal use only.
For at ROYAL SCHOOL OF VETERINARY STUDIES on June 5, 2013. bloodjournal.hematologylibrary.orgFrom 
cells, class IICD11chigh (referred to as conventional DCs), and
CD11cdimPDCA-1 plasmacytoid DCs (pDCs) also failed to dem-
onstrate significant differences within the marrow. There was a
trend toward a decrease in both EGFP-positive Ly6G and
CD11b populations (mainly granulocytes) within the blood of
anti-CSF1R–treated animals (Figure 1C).
Peripheral blood monocytes have previously been shown to be
segregated into 2 functional CSF1R (CD115) subsets, based upon
their differential expression of Gr1, an antigenic determinant
shared by Ly6G and Ly6C surface molecules.15 The Gr1neg
population selectively replenishes resident tissue macrophages,
whereas the Gr1 cells are short-lived and are selectively recruited
to inflammatory sites.16 Thus, to further dissect the effects of
anti-CSF1R treatment on blood myeloid populations, we used
3-color flow cytometry to examine the expression of Gr1 and F4/80
in association with EGFP within the blood of Ab-treated animals.
Interestingly, analysis of EGFP and F4/80 expression in combina-
tion revealed that the csf1r-EGFP marker divided monocytes into
2 populations, which also differed in their expression of F4/80
antigen (Figure 1D). Furthermore, the F4/80high, EGFPhigh mono-
cytes were also Gr1neg. After 1 week of treatment, the monocyte
populations were not changed significantly (not shown), but after
3 weeks, the F4/80highEGFPhighGr1neg population was selectively
and completely depleted by anti-CSF1R treatment. By contrast, the
F4/80int monocytes were Gr1, and this population was actually
increased by the anti-CSF1R treatment (Figure 1D), so that the
total monocyte count as a proportion of total leukocytes was
maintained. The csf1r-EGFP transgene expression also detects
circulating granulocytes,11 which share Gr1, but lack F4/80; these
were not significantly depleted by anti-CSF1R treatment (Figure
1D). The data demonstrate that anti-CSF1R acts to prevent the
maturation of the Gr monocytes into Gr1/F4/80high monocytes.
The effect of anti-CSF1R treatment on resident macrophage
populations
CSF-1–deficient and CSF1R-deficient mice exhibit a substantial
depletion of populations of F4/80-positive macrophages in many
organs of the body,4 Therefore, we next examined the effect of
anti-CSF1R treatment on resident CSF1R-expressing populations
in peripheral tissues of the MacGreen mice. Tissues from Ab-
treated mice were harvested and examined by fluorescent micros-
copy for csf1r-EGFP transgene reporter expression. Anti-CSF1R
treatment caused an almost complete reduction of the EGFP-
positive stellate macrophage populations in liver, skin (Langerhans
cells of the epidermis and the abundant population of presumed
macrophages of the dermis), small intestine, stomach, colon,
bladder, pancreas, testis, and kidney, compared with tissues from
control rat IgG-treated animals (Figure 2A-H and supplemental
Figures 3-5). Examination of hematoxylin and eosin–stained
sections showed no increase in the number of pyknotic nuclei of
apoptotic cells in these tissues, nor was there any overt pathology
arising from the deletion of the tissue-macrophage populations
(data not shown). In particular, there was no evidence of any
infiltration of inflammatory monocytes or granulocytes. Both
myeloid populations would likely be recruited if there was more
extensive cell death and tissue damage. Both of these populations
were positive for the csf1r-EGFP transgene,11 and yet, there was
almost a complete removal of all transgene expression in organs
such as the liver, gut, and kidney. Anti-CSF1R treatment had no
effect on the brain-macrophage populations, neither those of the
meninges and choroid plexus, nor the microglia of the brain
parenchyma (Figure 3A-B). This was in marked contrast to the
retina, in which the microglia were undetectable after anti-CSF1R
treatment (Figure 3C). Three other organs, where there was
minimal depletion of the csf1r-EGFP–positive macrophage popula-
tions, were the lung parenchyma and the ovary and uterus (Figure
3D-F). In the lung, the apparent overall abundance of interstitial
csf1r-EGFP–positive cells was unchanged by the Ab treatment
(Figure 3D). However, within the major airways, bronchoalveolar
macrophages were clearly highlighted by the csf1r-EGFP trans-
gene in control mice; most sections contained small numbers of
such cells (supplemental Figure 6). By contrast, no cells clearly
located within the airway space were detectable in comparable
sections of lung from Ab-treated mice (not shown).
Although the anti-CSF1R treatment did not cause a global
change in myeloid cellularity in lymphoid tissues (Figure 1), there
was an apparent impact on certain subpopulations evident in tissue
sections. In the spleen, a subset of especially bright csf1r-EGFP–
positive cells surrounding lymphoid follicles (not shown) and, in
the mesenteric lymph node, a population underlying the subcapsu-
lar sinus were depleted (supplemental Figure 4). Conversely, red
pulp macrophages of spleen, interdigitating cells (resident DCs),
medullary macrophages, and tingible body cells in the lymph nodes
(supplemental Figure 4) were unaffected.
Figure 2. Anti-CSF1R antibody mediated depletion of CSF1R-
EGFP tissue macrophages. MacGreen mice were treated with
400 g of anti-CSF1R or control antibody (rat IgG) administered
by intraperitoneal injection, thrice weekly for 3 weeks. Fluorescent
micrographs comparing EGFP expression in 12-m sections of
liver (A), skin (B), small intestine (C), colon (D), bladder (E),
pancreas (F), testis (G), and kidney (H) from anti-CSF1R or rat
IgG-treated mice are shown. All images are 20magnification.
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The effect of anti-CSF1R treatment on inflammatory
macrophage recruitment
The lack of impact of the anti-CSF1R treatment on the inflamma-
tory monocyte subset leads to the prediction that the treatment
would not affect inflammatory processes, and might even exacer-
bate them. To test this prediction, we examined the effect of
anti-CSF1R treatment on monocyte/macrophage recruitment in
several models of inflammation. Anti-CSF1R treatment had no
effect on the recruitment of monocyte/macrophages into the
peritoneal cavity in response to thioglycollate broth, nor monocyte/
macrophage recruitment into the lung in response to intratracheal
LPS installation (Figure 4A-B). In both models, granulocyte
recruitment actually appeared enhanced in the anti-CSF1R–treated
animals, compared with control treated, although this was only
significant in the LPS model. We also examined the effect of
anti-CSF1R treatment on wound healing using a model of macro-
phage-dependent wound repair. Polidocanol detergent was used to
strip the epithelial layer from one side of the nasal septum, while
the contralateral side served as control tissue. In this model, cellular
reconstitution occurs within 7 days. Neither the timing nor
efficiency of tissue regeneration was affected by anti-CSF1R
pretreatment (Figure 4C).
Having observed no change in the influx of innate macrophage
populations in either inflammatory recruitment models, or in the
wound-healing model, we next investigated the effects of anti-
CSF1R treatment on macrophage recruitment in 2 tumor models
(eg, AE5MG and Lewis Lung carcinoma), in which substantial
recruitment of macrophages occurs. Tumor-associated macro-
phages (TAMs) are said to be alternatively activated,17 but it is not
clear whether they are inflammatory or are simply resident
macrophages populating a new organ (ie, the tumor). We used a
subcutaneous AE5MG mesothelioma model in the MacGreen
mice, in which the csf1r-EGFP marker provides a striking indica-
tion of the recruitment of macrophages into the tumor. In the
mesothelioma tumor site, the csf1r-EGFP–positive cells were
numerous, approximately 10%-15% of the total tumor space, and
were distributed throughout the tumor. In the Lewis lung carcinoma
(LLC) metastatic lesions growing in the lung, the csf1r-EGFP
marker labels a similar proportion of the tumor volume (supplemen-
tal Figure 7). In each case, once the tumors were established,
anti-CSF1R (or rat Ig control) treatment was initiated and its effects
on the number of tumor-associated macrophages (TAMs) and
tumor growth was monitored. Anti-CSF1R treatment greatly
reduced the number of TAMs in the mesothelioma based on laser
scanning cytometric quantitation of either GFP- or F4/80-stained
sections (Figure 5A-B). In LLC, there was a similar impact, except
that in some sections, there appeared to be an intense EGFP-
positive inflammatory focus around the tumor periphery, which
was unaffected (supplemental Figure 6). The anti-CSF1R treatment
had no significant effect on tumor growth or final tumor burden in
the AE5MG model (Figure 5C) or in the LLC model (not shown).
The effect of anti-CSF1R treatment on acute GVHD
We next wished to determine the impact of removal of the resident
monocyte population and tissue macrophages in a model of
immune-mediated inflammation. Graft-versus-host disease
(GVHD), the major complication of bone marrow (BM) transplan-
tation, is initiated by donor T cells, which recognize alloantigen
expressed on residual host APCs. We used the well-established B6
into B6D2F1 model of acute GVHD, in which B6D2F1 recipients
were first treated with anti-CSF1R or control antibody, then lethally
irradiated (1100 cGy) and transplanted with allogeneic C57B6
T cell–depleted (TCD) BM with or without splenic T cells. Quite
unexpectedly, the depletion of host macrophages by anti-CSF1R
treatment resulted in a very significant acceleration of acute GVHD
mortality (Figure 6A). Examination of GVHD target tissues,
including the liver, colon, and small gut, taken 7 days after
transplantation, confirmed the absence of F4/80-expressing cells in
tissues from the anti-CSF1R–treated recipients (Figure 6B). His-
topathologic evaluation of these tissues revealed increased gastro-
intestinal pathology associated with the treated transplant recipi-
ents at this time point (Figure 6C). In an effort to explain the
increased pathology, we examined splenic T-cell cytokine produc-
tion after transplantation. At day 7 after transplantation, interferon
(IFN) and tumor necrosis factor (TNF) were both at significantly
higher levels in the tissue culture supernatants of CD3-stimulated
splenocytes purified from anti-CSF1R–treated recipients, com-
pared with control rat IgG-treated recipients (Figure 6D). This
enhanced cytokine production was attributable to an increase in the
frequency of IFN- and TNF-expressing cells within both CD4 and
CD8 T-cell compartments (Figure 6E). Although the actual number
of CD4 effector cells was similar in control and anti-CSF1R–
treated recipients, there was a significant decrease in FoxP3-
positive regulatory T (Treg) cells in both the spleen and peripheral
lymph nodes of treated recipients, resulting in a decreased CD4
Treg:effector ratio (Figure 6F). These data are consistent with the
observation that anti-CSF1R does not deplete inflammatory mono-
cytes and hence does not prevent macrophage-mediated pathology.
Conversely, the CSF-1-dependent resident macrophages appear to
contribute immunosuppressive activity that restricts alloreactive
T-cell activation.
Figure 3. Tissue-specific depletion of CSF1R-EGFP resident
tissue macrophages with anti-CSF1R antibody. MacGreen
mice were treated with 400 g of anti-CSF1R or control antibody
(rat IgG) administered by IP injection, thrice weekly for 3 weeks.
Shown are fluorescent micrographs of 12-m sections of brain tissue
showing parenchyma (A) and meninges (B), and of retina (C), lung
(D), ovary (E), and uterus (F), from anti-CSF1R or rat IgG-treated
mice.All images are 20magnification.
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Discussion
The data presented herein unify and extend previous findings
concerning the role of CSF1R signaling in monocyte-macrophage
development. We have used prolonged treatment with anti-CSF1R
Ab to deplete the large majority of tissue macrophage populations.
The M279 anti-CSF1R mAb is a rat IgG1, a subclass that does not
fix complement. By contrast to other approaches, such as the
various transgenic lines expressing the diptheria toxin receptor in
myeloid cells,18 the so-called MAFIA mice,19 or the use of toxic
liposomes,20 the Ab did not induce an immediate loss of tissue
macrophages or blood monocytes, nor was there any evidence of
local inflammation. It clearly does not deplete all of the cells that
bear the CSF1R on their surface, because it had no effect on the
inflammatory monocytes or their marrow precursors. Because one
function of apoptosis is to attract monocytes to clear the dying
cells,21 and because the antibody did not actually prevent the
recruitment of inflammatory monocytes in any of the models we
have studied, acute apoptosis is an unlikely explanation for the
observed complete depletion of csf1r-EGFP–positive cells from
most organs.
Instead, we suggest that the Ab depletes the subset of mono-
cytes that has been shown, by others, to be committed to a resident
tissue macrophage fate16 and thereby prevents replacement of
tissue macrophages as they turn over normally. The depletion of the
resident monocytes was balanced by an increase in the inflamma-
tory monocytes, so that total monocyte numbers were unaffected.
The proposed model is consistent with evidence of a precursor
relationship between the immature inflammatory monocyte and
mature resident monocytes in vivo.15,22 The time course of the
response to anti-CSF1R is also consistent with the proposed
mechanism. We did not see significant monocyte depletion after
1 week of treatment. Tacke et al22 used a labeled phagocytic tracer
in mice to demonstrate that Gr1high monocytes convert to Gr1neg
monocytes over a period of 5-7 days, and labeled Gr1neg monocytes
disappear from the circulation with a half-life of approximately
7 days. The ability of CSF-1 to promote monocyte maturation and
acquisition of the resident phenotype in vitro is well documented.15
Bogunovic et al have recently demonstrated that adoptively
transferred csf1r/ fetal liver cells into irradiated recipients gives
rise to Gr1high but not Gr1lo blood monocytes.23 So, the actions of
anti-CSF1R indicate that CSF-1, which is present at biologically
active concentrations in the circulation, is the missing factor22 that
promotes the maturation of the Gr1high to the Gr1neg monocyte. The
so-called resident monocyte is characterized by a CD115Gr-1neg
phenotype and high expression of CX3CR1 (and of a CX3CR1-
EGFP reporter transgene)16 Herein, we add 2 additional phenotypic
characteristics to these cells in that they have 3-4-fold higher
expression of both the F4/80 macrophage-specific antigen and the
csf1r-EGFP transgene (Figure 1). The mechanism underlying
increased expression of the csf1r-EGFP reporter with monocyte
maturation is unclear; it presumably reflects increased expression
of macrophage-specific or -inducible transcription factors that act
upon the csf1r promoter and intragenic enhancer.10 However, we
have confirmed in other studies that the Gr1high, csf1r-EGFPlow
monocytes are selectively recruited into the peritoneum in response
to foreign bodies,24 so it provides a convenient additional marker
for studies of monocyte-macrophage function during inflammation.
We cannot eliminate the possibility that anti-CSF1R accelerates
the turnover of tissue macrophages, in addition to its impact on
their monocytic precursors. However, the time frame for the
depletion of tissue macrophages is consistent with many studies on
the turnover of tissue macrophages, in which alveolar macrophages
turned over on average every 27 days, and Kupffer cells of the liver
every 21 days.25,26 Monocyte and tissue macrophage numbers
increase rapidly (within 4 days) after intravenous CSF-1 injec-
tion,27 which we would now suggest is due to monocyte maturation
rather than increased production. We noted complete depletion of
the alveolar macrophages in the airways in sections of lung after Ab
administration, supporting the view that they are CSF-1 depen-
dent.28 This is not incompatible with recent evidence that they are
not replaced directly from monocytes29; it may mean that they
depend more on local CSF-1 production and are produced locally.
By contrast, the interstitial csf1r-EGFP–positive cells of the lung
remained unaffected by the Ab treatment (Figure 3D). These cells
also appear not to be derived directly from monocytes in the steady
Figure 4. Inflammation-mediated myeloid cell recruitment
and macrophage-mediated wound healing are unaffected by
anti-CSF1R treatment. (A) Anti-CSF1R and rat IgG mAb-treated
MacGreen mice were administered thioglycollate broth and cells
within the peritoneal cavity collected by lavage 5 days later. Cells
were counted, and 2-color flow cytometry was used to enumerate
monocyte and granulocyte numbers. (B) BAL fluid was collected
24 and 48 hours after intratracheal instillation of LPS in anti-
CSF1R and rat IgG mAb-treated MacGreen mice. Cells were
counted, and 2-color flow cytometry was used to enumerate
monocyte and granulocyte numbers. (C) Polidocanol detergent
was used to strip the epithelial lining from one side of the nasal
septum, with the contralateral side used as a control. Image
shows nasal septum from anti-CSF1R and rat IgG-treated ani-
mals 9 days after polidocanol administration. Bar represents
200 m.
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state, and, in contrast to alveolar macrophages, presumably do not
require CSF-1 signaling.29
The csf1r-EGFP transgene is expressed in all myeloid cells,
including all currently described subsets of DCs.10-12 The anti-
CSF1R Ab treatment depleted most EGFP-positive cells in the
majority of organs. Among the most dramatic effects was the
almost complete absence of EGFP-positive cells from the wall of
the GI tract after anti-CSF1R treatment (Figure 2C-D and supple-
mental Figure 5). Lamina propria macrophages are the largest
macrophage population in the body.1,2 There is an almost complete
overlap between the macrophage-specific F4/80 antigen and CD11c
in this location, as well as complete overlap of csf1r-EGFP
transgene and F4/80.30 Several groups have recognized that the
lamina propria mononuclear phagocytes can be divided into those
that can stimulate and those that repress T cell–mediated immune
responses.31,32 Based on the absence of EGFP and F4/80 expression
within the gut (Figures 2C-D,6B and supplemental Figure 5),
anti-CSF1R Ab treatment removes both populations. Notably, the
lamina propria mononuclear phagocytes are apparently derived
from circulating monocytes in adoptive transfer studies33 and are
absent in csf1op/op and csf1r/ mice.4
The macrophage populations of the dermis and epidermis,
including Langerhans cells, were also completely depleted by the
anti-CSF1R treatment (Figure 2B), in keeping with their absence
from csf1r/ mice.4 In inflamed skin, these cells have been shown
to be replenished from circulating Gr-1 monocytes: the inflamma-
tory subset.34 Our study suggests that in the normal steady state,
when they perhaps turn over much more slowly, skin macrophage
populations might actually be replenished from the resident
monocyte population. However, Chorro et al35 have suggested that
Langerhans cells are established from a wave of migratory
progenitors shortly after birth and thereafter are replenished by
local proliferation. So, the alternative view is that the local
progenitor is CSF-1 dependent. In any case, the turnover of these
cells would appear to be relatively rapid in the steady state, and the
Ab treatment provides a novel model for the study of myeloid
APCs of the skin.
Similarly, in the brain, microglia are believed to be replenished
from the circulating monocyte pool only under inflammatory
conditions, and in this circumstance, the Gr-1 inflammatory
monocytes appear to be the precursors.36 We saw no effect of the
anti-CSF1R Ab on brain microglia, but the microglia of the retina
were completely depleted by the Ab (Figure 3C). This difference
may be a function of the blood-brain barrier; however, it could also
be an issue of the rate of turnover and replacement, because only
23% of brain microglia are of donor origin in BM chimeras
6 months after transplantation.37 The majority of the macrophage
populations of the spleen and lymph nodes were unaffected by the
Ab treatment, and by extension, are probably not derived from a
CSF-1–dependent resident monocyte or controlled by local CSF-1
production. The likely explanation is that these sites are seeded by
progenitors divergent from more mature monocytes that also
proliferate locally.38,39 The exception is the marginal zone macro-
phages of the spleen, and the subcapsular sinus macrophages of the
lymph node, which seem to express the csf1r-EGFP transgene at
high levels and which were depleted in Ab-treated animals.
Marginal-zone macrophages have been shown previously to be
CSF-1 dependent.40
The simplest explanation for the failure of the Ab treatment to
alter the course of inflammation in any of the models we have
tested is that it does not remove the inflammatory monocyte subset.
Importantly, because CSF-1 is elevated in the circulation in many
inflammatory states,4,5 the data demonstrate that CSF-1 is not
required for increased monocytopoiesis in response to inflamma-
tory stimuli. The failure of anti-CSF1R to inhibit thioglycollate-
elicited macrophage recruitment to the peritoneum contrasted with
a report that an orally available CSF-1 kinase inhibitor, GW2580,
inhibited this response.7 Subsequently, GW2580 was reported to
inhibit many inflammatory responses in rat models.8 But, in
complete contrast to the anti-CSF1R Ab in our study, GW2580
actually caused a substantial rise in blood monocyte count.
GW2580 is an effective inhibitor of the related flt3 and c-kit
tyrosine kinases;41 thus, the contrast with the actions of anti-CSF1R
suggests that the inhibitor does not act specifically via CSF1R.
Figure 5. Treatment with anti-CSF1R prevented the recruitment of EGFP cells into tumor mass. MacGreen mice were inoculated subcutaneously with
1  106 mesothelioma cells and tumor nodules allowed to develop until just palpable, at which point treatment with anti-CSF1R or isotype antibody was commenced.
(A) csf1r-EGFP and F4/80 expression in tumor (magnification,20) and (B) laser scanning quantitation of csf1r-EGFP expression and F4/80 staining within tumor. (C) Analysis
of tumor growth.
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Another inhibitor described more recently, JNJ-28312141,42 also
had a different effect to the anti-CSF1R Ab, causing acute depletion
of tissue macrophages detected with F4/80 within 4 days. In this
case, one might be concerned with the marker used, because F4/80
is itself CSF-1 dependent.27 JNJ-28312141 was proposed as a
cancer therapeutic, with the proposed mechanism based upon TAM
depletion.42 Again, we suspect that the inhibitor could act on targets
other than CSF1R, but it might also be the case that it penetrates
more effectively to tissue macrophages—and they are, in fact,
CSF-1 dependent for survival.
In the epithelial damage wound healing model (Figure 4C), we
saw no impact of the Ab treatment on macrophage recruitment or
repair. We might also consider the ovary and uterus, where
anti-CSF1R had no impact on the abundant csf1r-EGFP–positive
populations (Figure 3), as forms of tissue repair, because there is
considerable tissue turnover through the estrous cycle. By contrast,
others have found that anti-CSF1R Ab AFS98 can impair recruit-
ment and local proliferation in wound healing/repair, for example,
after injury in the kidney and in muscle.43,44 In these cases, and in
the tumors, macrophage proliferation in response to CSF-1 pro-
duced locally could be involved.43 There is a substantial body of
literature on the cellular phenotype of TAMs, much of it focused on
the existence of an alternative activation state referred to as the M2
type.17 The csf1r-EGFP transgene provides a striking view of the
extent of macrophage infiltration in tumors (Figure 5 and supple-
mental Figure 6). However, the substantive depletion of TAMs by
anti-CSF1R treatment suggests that they could primarily be
resident type cells. In the 2 tumor models we studied, and with the
timing and conditions employed, there was no impact of substantial
macrophage depletion on tumor growth. According to our model,
anti-CSF1R acts to deplete the macrophages already present in the
established tumors, and any impact on the growth of the rapidly
growing established mesothelioma tumor we studied would likely
be delayed beyond the 3-week time course examined. In the LLC
metastatic lung model, although the Ab-depleted csf1r-EGFP
macrophages from the tumor mass (supplemental Figure 6), it did
not prevent their accumulation around the invasion front, and it did
not deplete lung-parenchymal macrophages. So, the LLC tumors
were not deprived entirely of potential trophic actions of macro-
phages. The abundant evidence that macrophages are required for
tumor growth in human and experimental tumors13,17 suggests that
such depletion could be of benefit to cancer patients, and CSF1R
remains a candidate anticancer drug target.
Others have also concluded that the inflammatory monocyte
subset contains the major effectors in experimental autoimmune
encephalitis45 and lupus nephritis.46 Interestingly, although anti-
CSF1R does not deplete the total monocyte pool in these patholo-
gies, CSF-1 treatment can greatly expand it,27 and it is the
inflammatory monocyte subset that is increased.46 Thus, the
production of inflammatory monocytes in the steady state is
responsive to, but not dependent upon, circulating CSF-1 signaling
through the CSF-1 receptor. The model in which there was a
striking effect of anti-CSF1R was GVHD. The most important
finding in terms of the current study is that the Ab did not prevent
pathology in an immune-mediated inflammatory model, reinforc-
ing the fact that CSF-1 signaling does not have a nonredundant
Figure 6. Treatment with anti-CSF1R exacerbates acute GVHD. (A) Survival by Kaplan-Meier analysis. Irradiated anti-CSF1R and rat IgG mAb-treated B6D2F1 recipients
were transplanted with BM and T cells from C57Bl/6 mice as described in supplemental Methods (rat IgG allo and anti-CSF1R allo; n  21/treatment). Irradiated
anti-CSF1R–treated B6D2F1 received TCD BM and served as non-GVHD controls (n  8). ***P  .0001, rat IgG allo vs anti-CSF1R allo. (B) F4/80 staining in liver, colon, and
small gut taken from rat IgG allo and anti-CSF1R allo recipients 7 days after transplantation. (C) Liver and gut histopathology was determined by semiquantitative histology as
described in supplemental Methods. (D) Unfractionated splenocytes from rat IgG allo and anti-CSF1R allo recipients 7 days after transplantation were cultured with CD3 and
IFN and TNF determined in 24-hour tissue-culture supernatant or (E) cultured with CD3 and brefeldin and IFN and TNF measured by intracellular cytokine staining.
(F) CD4FoxP3 T effectors and CD4FoxP3 Treg were enumerated in spleens and lymph nodes from rat IgG allo and anti-CSF1R allo recipients 7 days after transplantation.
In all histograms, the white bar represents rat IgG allo recipients; the black bar, anti-CSF1R allo recipients; and the hatched bar, anti-CSF1R TCD recipients.
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function in inflammation. The unexpected finding was that the Ab
treatment actually exacerbated the disease. In the GVHD model,
inflammation is driven by activation of host APCs, stimulation of
alloreactive donor T cell–derived T helper 1 cytokines and the
release of TLR ligands from the irradiated GI tract.47 Anti-CSF1R
pretreatment of BM graft recipients actually increased T-cell
activation and proinflammatory cytokine production, decreased
numbers of regulatory T cells (Figure 6), and generated a compara-
tive increase in the inflammatory monocyte subset (Figure 1D).
Together, these changes provide a possible explanation of the
accelerated pathology. We and others have shown that CSF-1 is a
mediator of the immunosuppression associated with cancer-bearing
or chronic infection.48,49 Dissection of the precise mechanism of
action of anti-CSF1R on allogeneic T-cell stimulation is beyond the
scope of this study; it likely involves the removal of tolerogenic
APCs in the wall of the gut,31 as well as CSF-1–dependent myeloid
suppressor cells49 that would constrain the development of donor-
derived alloreactive T cells. The treatment is equivalent in some
respects to the knockout of the CSF-1–responsive F4/80 gene,
which also worsens autoimmune-mediated pathology and reduces
production of regulatory T cells.50 From a therapeutic viewpoint,
one might consider using CSF-1 to ameliorate disease, although
such treatment would also expand the inflammatory monocyte
pool.45,46 Conversely, one might consider anti-CSF1R as an ap-
proach to restoring immune responses in immunosuppressed
patients.
The final question is what is the exact function of CSF1R
signaling in resident monocytes. One of the known actions of
CSF-1 is to maintain macrophage survival. Lagasse and Weiss-
mann reported that transgenic expression of the antiapoptotic Bcl-2
gene in myeloid cells was sufficient to counter, in part, the op/op
mutation, permitting replenishment of many tissue-macrophage
populations.51 As noted above, the resident monocytes are compara-
tively long lived in the circulation, whereas their precursors, the
inflammatory monocytes, are short lived.22 Logically, the large
majority of monocytes that enter the circulation must exit or die,
and only a small subset matures to become resident type cells. In
keeping with this view, anti-CSF1R did not escalate circulating
monocyte numbers and did not cause any increase in inflammatory
monocytes in tissues, even though it did not prevent their infiltra-
tion in response to a stimulus. CSF-1 could simply act to maintain
the survival and increase the half-life of immature monocytes,
thereby exerting a permissive, rather than an instructive, role in
monocyte maturation. Whatever the mechanism, our data suggest
that the ability of systemic treatment with CSF-1 to increase
monocyte numbers and tissue mononuclear-phagocyte popula-
tions27,52 is a consequence of enhanced differentiation of the
short-lived Gr-1 monocytes, rather than increased production of
monocytes from the BM. Indeed, Sudo et al14 have suggested that
stem cell factor, acting through c-kit, is more important than CSF-1
for the proliferation of BM monocyte progenitors.
The analysis of animals treated with anti-CSF1R Abs strongly
supports the emerging view of functional monocyte heterogeneity
and provides a unique model in which tissue macrophage popula-
tions can be selectively depleted. At least in the steady state, there is
remarkably little impact on the health of the animals, and this may
represent a novel approach to modulate immunologic responses in
vivo.
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